Armored immune cells take on tough lymphoma in early trial
NCT ID NCT07368270
First seen Jan 28, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This early-stage study tests a new type of CAR-T cell therapy that has been 'armored' with an anti-PD1 feature to help it fight cancer better. It is for adults with diffuse large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to see if the treatment is safe and to measure how well it shrinks tumors. About 30 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Suzhou Hongci Hematology Hospital
RECRUITINGSuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.